Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 740

1.

Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI.

Hanneman K, Alberdi HV, Karur GR, Tselios K, Harvey PJ, Gladman DD, Akhtari S, Osuntokun T, Wald RM, Thavendiranathan P, Butany J, Urowitz MB.

JACC Cardiovasc Imaging. 2019 Nov 6. pii: S1936-878X(19)30937-4. doi: 10.1016/j.jcmg.2019.09.014. [Epub ahead of print] No abstract available.

PMID:
31734202
2.

Prediction of damage accrual in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI).

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin PR, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

Arthritis Rheumatol. 2019 Oct 21. doi: 10.1002/art.41144. [Epub ahead of print]

PMID:
31631584
3.

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.

Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, van Vollenhoven RF, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Autoimmun. 2019 Oct 17:102340. doi: 10.1016/j.jaut.2019.102340. [Epub ahead of print]

4.

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.

Orbai AM, McInnes IB, Coates LC, Husni ME, Gladman DD, Gossec L, Pricop L, Chambenoit O, Meng X, Mease PJ.

J Rheumatol. 2019 Oct 15. pii: jrheum.190507. doi: 10.3899/jrheum.190507. [Epub ahead of print]

5.

Liver Abnormalities in Patients with Psoriatic Arthritis.

Pakchotanon R, Ye Y, Cook RJ, Chandran V, Gladman DD.

J Rheumatol. 2019 Oct 15. pii: jrheum.181312. doi: 10.3899/jrheum.181312. [Epub ahead of print]

PMID:
31615918
6.

Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach.

Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Farewell V, Stoll T, Buyon J, Clarke AE.

Arthritis Care Res (Hoboken). 2019 Oct 14. doi: 10.1002/acr.24092. [Epub ahead of print]

PMID:
31609532
7.

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Feld J, Ye JY, Chandran V, Inman RD, Haroon N, Cook R, Gladman DD.

Rheumatology (Oxford). 2019 Oct 8. pii: kez457. doi: 10.1093/rheumatology/kez457. [Epub ahead of print]

PMID:
31593590
8.

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.

Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S, Wang Y, Hsia EC, Gladman DD, Ritchlin CT.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24046. [Epub ahead of print]

PMID:
31421033
9.

Peripheral nervous system disease in Systemic Lupus Erythematosus: Results from an international, inception cohort study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Svenungsson E, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Rheumatol. 2019 Aug 7. doi: 10.1002/art.41070. [Epub ahead of print]

PMID:
31390162
10.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
11.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

12.

Response to: 'Can biomarkers differentiate psoriatic arthritis from osteoarthritis?' by Tian et al.

Chandran V, Cook RJ, Gladman DD.

Ann Rheum Dis. 2019 Jul 4. pii: annrheumdis-2019-215762. doi: 10.1136/annrheumdis-2019-215762. [Epub ahead of print] No abstract available.

PMID:
31272941
13.

Dr. Tselios, et al, reply.

Tselios K, Gladman DD, Harvey P, Akhtari S, Su J, Urowitz MB.

J Rheumatol. 2019 Oct;46(10):1422. doi: 10.3899/jrheum.190255. Epub 2019 Jul 1. No abstract available.

PMID:
31263072
14.

Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE.

Webber D, Cao J, Dominguez D, Gladman DD, Levy DM, Ng L, Paterson AD, Touma Z, Urowitz MB, Wither JE, Silverman ED, Hiraki LT.

Rheumatology (Oxford). 2019 Jun 24. pii: kez220. doi: 10.1093/rheumatology/kez220. [Epub ahead of print]

PMID:
31236574
15.

Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.

Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J Jr, Shete A, Bruin G.

J Rheumatol. 2019 Jun 15. pii: jrheum.190116. doi: 10.3899/jrheum.190116. [Epub ahead of print]

PMID:
31203228
16.

Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity.

Perruccio AV, Got M, Li S, Ye Y, Gladman DD, Chandran V.

J Rheumatol. 2019 Jun 15. pii: jrheum.181472. doi: 10.3899/jrheum.181472. [Epub ahead of print]

PMID:
31203221
17.

The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis.

Fei JZ, Perruccio AV, Ye JY, Gladman DD, Chandran V.

Rheumatology (Oxford). 2019 Jun 14. pii: kez202. doi: 10.1093/rheumatology/kez202. [Epub ahead of print]

PMID:
31199486
18.

GRAPPA 2018 Project Report.

Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2019 Jun;95:54-57. doi: 10.3899/jrheum.190121.

PMID:
31154406
19.

Best-practice Indicators in Psoriatic Disease Care.

Helliwell PS, Favier G, Gladman DD, Soriano ER, Kirkham BW, Coates LC, Puig L, Boehncke WH, Thaçi D.

J Rheumatol Suppl. 2019 Jun;95:38-45. doi: 10.3899/jrheum.190120.

PMID:
31154403
20.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W.

J Rheumatol Suppl. 2019 Jun;95:33-37. doi: 10.3899/jrheum.190122.

PMID:
31154402
21.

Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, O'Sullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald O.

J Rheumatol Suppl. 2019 Jun;95:11-19. doi: 10.3899/jrheum.190118.

PMID:
31154399
22.

Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Callis Duffin K, Gladman DD, Gottlieb AB, Goel N.

J Rheumatol Suppl. 2019 Jun;95:1-3. doi: 10.3899/jrheum.190112.

PMID:
31154397
23.

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.

Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R.

Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930.

24.

A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire.

Johnson K, Ye JY, Chandran V, Gladman DD.

Semin Arthritis Rheum. 2019 Oct;49(2):241-245. doi: 10.1016/j.semarthrit.2019.04.001. Epub 2019 Apr 19.

PMID:
31101369
25.

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.

Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ.

Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.

26.

Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC.

Patrick MT, Stuart PE, Raja K, Chi S, He Z, Voorhees JJ, Tejasvi T, Gudjonsson JE, Kahlenberg JM, Chandran V, Rahman P, Gladman DD, Nair RP, Elder JT, Tsoi LC.

Front Genet. 2019 Apr 11;10:304. doi: 10.3389/fgene.2019.00304. eCollection 2019.

27.

All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013).

Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M.

Ann Rheum Dis. 2019 Jun;78(6):802-806. doi: 10.1136/annrheumdis-2018-214802. Epub 2019 Apr 16.

PMID:
30992296
28.

Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

J Rheumatol. 2019 Apr 15. pii: jrheum.181338. doi: 10.3899/jrheum.181338. [Epub ahead of print]

PMID:
30988130
29.

Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.

Chandran V, Abji F, Perruccio AV, Gandhi R, Li S, Cook RJ, Gladman DD.

Ann Rheum Dis. 2019 Jun;78(6):796-801. doi: 10.1136/annrheumdis-2018-214737. Epub 2019 Mar 25.

PMID:
30910989
30.

The development of a modified Psoriatic Arthritis Disease Activity Score (mPASDAS) using SF-12 as a measure of quality of life.

Perruccio AV, Got M, Li S, Ye Y, Gladman DD, Chandran V.

Arthritis Care Res (Hoboken). 2019 Mar 15. doi: 10.1002/acr.23876. [Epub ahead of print]

PMID:
30875460
31.

Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L.

J Rheumatol. 2019 Sep;46(9):1089-1096. doi: 10.3899/jrheum.180971. Epub 2019 Mar 1.

32.

Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.

Pollock RA, Zaman L, Chandran V, Gladman DD.

PLoS One. 2019 Feb 19;14(2):e0212043. doi: 10.1371/journal.pone.0212043. eCollection 2019.

33.

Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

Arthritis Rheumatol. 2019 Aug;71(8):1297-1307. doi: 10.1002/art.40859. Epub 2019 May 29.

PMID:
30771242
34.

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Aug;46(8):996-1005. doi: 10.3899/jrheum.181089. Epub 2019 Feb 15.

PMID:
30770518
35.

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón G, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet E.

Rheumatology (Oxford). 2019 Jul 1;58(7):1259-1267. doi: 10.1093/rheumatology/kez014.

PMID:
30753683
36.

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.

Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB.

Arthritis Rheumatol. 2019 Jul;71(7):1112-1124. doi: 10.1002/art.40851. Epub 2019 May 28.

37.

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019.

38.

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. eCollection 2019.

39.

Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story.

Urowitz MB, Su J, Gladman DD.

J Rheumatol. 2019 Feb 1. pii: jrheum.180986. doi: 10.3899/jrheum.180986. [Epub ahead of print]

PMID:
30709950
40.

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.

Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, Rathmann S, Shrom D, Marzo-Ortega H.

Arthritis Res Ther. 2019 Jan 29;21(1):38. doi: 10.1186/s13075-019-1831-0.

41.

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg DA, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Rheumatol. 2019 May;46(5):492-500. doi: 10.3899/jrheum.180713. Epub 2019 Jan 15.

42.

Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis.

Polachek A, Cook R, Chandran V, Gladman DD, Eder L.

Arthritis Res Ther. 2019 Jan 14;21(1):20. doi: 10.1186/s13075-019-1814-1.

43.

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.

Mendel A, Bernatsky SB, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon JP, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin PR, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet É.

Ann Rheum Dis. 2019 Jul;78(7):1010-1012. doi: 10.1136/annrheumdis-2018-214434. Epub 2018 Dec 20. No abstract available.

44.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.

PMID:
30554156
45.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Duffin KC, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2019 Aug;46(8):990-995. doi: 10.3899/jrheum.181077. Epub 2018 Dec 15.

PMID:
30554154
46.

Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls.

Polachek A, Polachek Shlomi I, Spitzer K, Pereira D, Ye JY, Chandran V, Laskin CA, Gladman DD.

Clin Rheumatol. 2019 Mar;38(3):895-902. doi: 10.1007/s10067-018-4385-7. Epub 2018 Dec 7.

PMID:
30535992
47.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

48.

Disease course patterns in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Lupus. 2019 Jan;28(1):114-122. doi: 10.1177/0961203318817132. Epub 2018 Dec 8.

PMID:
30526328
49.

What Is Axial Psoriatic Arthritis?

Feld J, Chandran V, Gladman DD.

J Rheumatol. 2018 Dec;45(12):1611-1613. doi: 10.3899/jrheum.180802. No abstract available.

PMID:
30504477
50.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30. Review.

PMID:
30499259

Supplemental Content

Loading ...
Support Center